Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Riverbridge Partners LLC

Riverbridge Partners LLC lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 7.0% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 222,734 shares of the medical research company's stock after selling 16,654 shares during the quarter. Riverbridge Partners LLC owned about 0.45% of Charles River Laboratories International worth $33,526,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in CRL. Asset Management One Co. Ltd. increased its stake in Charles River Laboratories International by 1.7% in the fourth quarter. Asset Management One Co. Ltd. now owns 18,918 shares of the medical research company's stock valued at $3,522,000 after purchasing an additional 315 shares during the last quarter. Vontobel Holding Ltd. acquired a new position in shares of Charles River Laboratories International during the fourth quarter valued at $335,000. Bryn Mawr Capital Management LLC increased its holdings in shares of Charles River Laboratories International by 1,871.2% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 35,659 shares of the medical research company's stock valued at $6,583,000 after purchasing an additional 33,850 shares during the period. Handelsbanken Fonder AB increased its holdings in shares of Charles River Laboratories International by 1.6% during the fourth quarter. Handelsbanken Fonder AB now owns 12,437 shares of the medical research company's stock valued at $2,296,000 after purchasing an additional 200 shares during the period. Finally, VisionPoint Advisory Group LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter valued at $1,751,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Analyst Ratings Changes

CRL has been the topic of a number of research analyst reports. Mizuho lowered their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a report on Wednesday, May 14th. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their target price for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Robert W. Baird lifted their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. Finally, JPMorgan Chase & Co. lowered their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and an average target price of $171.85.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Up 0.1%

NYSE:CRL opened at $145.24 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. The company has a market cap of $7.13 billion, a PE ratio of -223.44, a PEG ratio of 4.48 and a beta of 1.48. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The stock has a 50-day simple moving average of $130.79 and a 200 day simple moving average of $155.92.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The company had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. During the same period last year, the firm posted $2.27 earnings per share. The business's revenue was down 2.7% on a year-over-year basis. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.